Israel’s MISGAV, June 26, 2023, Escala Medical Ltd. is pleased to announce that the European Innovation Council has chosen it to receive a grant and equity investment totaling EUR 5.5 million. Escala is leading the revolution in pelvic organ prolapse (POP) treatment.

With the help of Escala Medical’s ground-breaking gadget, women with pelvic organ prolapse—a standard and crippling ailment affecting almost 50% of women worldwide—can now receive treatment without making an incision. With a technique that can be completed in 5-8 minutes while under local anesthesia, Escala’s creative strategy fills a sizable market need. After receiving FDA clearance, Escala has achieved a significant milestone by making its ground-breaking technology commercially available in the United States.

Most current surgical POP treatment techniques are invasive and best suited for advanced-stage prolapse. Women with early-stage symptoms or patients not candidates for surgery have not had viable incision-free alternatives until now. With its much-needed answer for these underserved communities, Escala Medical is revolutionizing POP treatment and offering a quicker and simpler option for professionals caring for patients with advanced-stage POP.

Excitedly adding, “With recent FDA clearance for our prolapse repair device, the EIC investment enables operations expansion and fulfills Escala’s mission of transforming POP treatment for countless women worldwide,” Dr. Edit Goldberg, CEO of Escala, expressed her satisfaction. Our game-changing technology offers a long-needed remedy, enabling early treatment and greatly enhancing millions of people’s quality of life.

The Escala Board of Directors’ Chair, Dr. Robert Auerbach, highlighted the business’ successes in the quickly developing FemTech market. The financing from the EIC, he said, “further validates Escala’s technology.” It helps us advance in our goal of giving patients with pelvic organ prolapse long-lasting, non-invasive treatments that significantly improve their quality of life.

Escala Medical, a FemTech business, is one of The Trendlines Group Ltd.’s portfolio companies (SGX: 42T; OTCQX: TRNLY). With the help of investors from Israel, the United States, the United Kingdom, and the Israel Innovation Authority, Escala is dedicated to providing its ground-breaking repair option for women with pelvic organ prolapse at all phases of the condition. Escala’s novel method will alter the approach to treating pelvic organ prolapse by moving the point of care from the hospital to the doctor’s office. The Food and Drug Administration (FDA) of the United States granted Escala regulatory approval.

We try our  best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by! 

Next Article

Previous articleVertex Ventures Healthcare Announces USD 200 Million Fund III to Promote Healthcare Innovation
Next articleSingapore-based Utu raises USD 33 million in Series B
Kshitij does business research and content writing for VCBay. Pursuing BBA from Symbiosis Center Of Management Studies (SCMS) Pune, he is skilled in Financial Modeling, Stock valuation and Microsoft Excel. He is passionate about Entrepreneurship and Finance.


Please enter your comment!
Please enter your name here